Most people start Ozempic to lose weight. The growing body of research suggests the drug may be doing considerably more, including directly reducing systemic inflammation through mechanisms that operate independently of how much weight is lost. This emerging picture has implications for a broader range of patients than just those seeking to reduce body weight.
What the SELECT Trial Found About Inflammation
The SELECT trial is the landmark study that established Ozempic’s cardiovascular benefits in people without diabetes. Published in 2023 and updated with final results in 2026, it enrolled 17,604 adults with overweight or obesity and established cardiovascular disease, but without type 2 diabetes.
Over a median of 33 months, participants on semaglutide experienced a 20 percent reduction in major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death, compared to placebo.
The inflammation findings within SELECT are equally striking. Semaglutide produced a 38 percent reduction in high-sensitivity CRP (hsCRP), a primary biomarker of systemic inflammation, compared to placebo. Critically, this reduction appeared early in the trial, before participants had lost substantial weight.
A prespecified subgroup analysis published in The Lancet in 2025 found that even among patients who lost less than 2 percent of body weight during the trial, semaglutide was associated with meaningful CRP reductions. This finding challenges the assumption that GLP-1 benefits are simply downstream of weight loss.
Ozempic’s Anti-Inflammatory Effect Independent of Weight Loss
The weight-independent inflammation data is one of the most scientifically interesting aspects of semaglutide research.
In standard obesity pharmacology, anti-inflammatory benefits are assumed to flow from fat reduction. Adipose tissue, particularly visceral fat around the organs, actively secretes pro-inflammatory cytokines, including TNF-alpha, IL-6, and CRP precursors. Reducing fat mass reduces this cytokine output, which lowers inflammation markers. This is the expected pathway.
What SELECT’s subgroup data suggests is that semaglutide has additional pathways that reduce inflammation directly, without requiring significant fat loss. The proposed mechanisms include:
GLP-1 receptor activation on immune cells. GLP-1 receptors are found on macrophages, T cells, and dendritic cells. When semaglutide activates these receptors, it shifts macrophages toward an anti-inflammatory (M2) phenotype and reduces inflammatory signaling in T cells.
NF-kB pathway inhibition. NF-kB is one of the central molecular switches that drives systemic inflammation. Several studies have found that GLP-1 receptor agonists suppress NF-kB activation, reducing downstream production of inflammatory cytokines.
Direct reduction of IL-6 and TNF-alpha. A 2024 systematic review and meta-analysis published in Frontiers in Cardiovascular Medicine confirmed that semaglutide reduces levels of IL-6 and TNF-alpha, two major pro-inflammatory cytokines, across multiple clinical trials.
CRP Reduction in Weight Loss Trials
The anti-inflammatory signal is not limited to the SELECT cardiovascular trial. Weight loss trials have documented similar CRP reductions.
In the STEP 1 trial, which enrolled adults with obesity (without established CVD), participants on semaglutide 2.4 mg experienced a 37.2 percent reduction in CRP at 68 weeks, compared to an 11.8 percent reduction in the placebo group. The magnitude of this difference is clinically significant: reducing hsCRP from a high-risk range (above 3.0 mg/L) into a lower-risk range has well-established associations with reduced cardiovascular event rates.
| Trial | CRP Reduction (Semaglutide) | CRP Reduction (Placebo) |
|---|---|---|
| SELECT (cardiovascular outcomes) | 38% | Not reported separately |
| STEP 1 (weight management) | 37.2% | 11.8% |
| SUSTAIN/PIONEER analyses | 25-40% | Variable |
Conditions Evidence Matrix: What GLP-1s May Help With
The following table maps the current state of evidence for semaglutide’s anti-inflammatory effects across different conditions. Evidence levels reflect the quality and consistency of published research as of mid-2026.
| Condition | Evidence Level | Key Trial or Finding | Clinical Status |
|---|---|---|---|
| Cardiovascular disease (MACE reduction) | Strong | SELECT trial: 20% MACE reduction, 38% CRP reduction vs placebo | FDA-approved indication (Wegovy) |
| Chronic kidney disease | Strong | FLOW trial: significant reduction in kidney disease progression | FDA-approved for CKD with T2D (Ozempic) |
| Non-alcoholic steatohepatitis (NASH) | Emerging | Phase 2 NASH trial: 59% vs 17% resolution of steatohepatitis; Phase 3 ongoing | Phase 3 trials ongoing (not yet approved) |
| Obstructive sleep apnea | Emerging | SURMOUNT-OSA: apnea events reduced ~60% vs placebo, beyond weight-loss prediction | FDA-approved for OSA (Zepbound/tirzepatide) |
| Alzheimer’s disease | Early/Promising | EVOKE and EVOKE Plus trials ongoing; preclinical neuroinflammation data positive | Phase 3 trials; results expected 2027 |
| Parkinson’s disease | Early | Small Phase 2 trial: slower motor decline on semaglutide vs placebo | Early clinical evidence only |
| Depression and neuropsychiatric conditions | Emerging | Observational data: lower depression diagnosis rates in GLP-1 users | No RCT confirmation; mechanistic plausibility |
| Rheumatoid arthritis | Insufficient | Case reports and small studies only; no RCTs | Hypothesis-generating only |
| Inflammatory bowel disease | Insufficient | Case reports of benefit and harm; conflicting signals | Insufficient evidence to recommend or avoid |
| Psoriasis | Insufficient | Case series suggest partial improvement; no controlled trial | Hypothesis-generating only |
How to read this matrix:
- Strong means large randomized controlled trials with consistent results across multiple studies.
- Emerging means at least one well-designed trial with positive results, with confirmatory research in progress.
- Early/Promising means phase 2 trial data or strong preclinical evidence, but Phase 3 results not yet available.
- Insufficient means only case reports or observational data without controlled trial confirmation.
Research is actively exploring GLP-1 effects in several additional inflammatory conditions. A 2024 systematic review and meta-analysis confirmed that semaglutide reduces IL-6 and TNF-alpha across multiple trial settings, suggesting broad anti-inflammatory activity that may extend to conditions not yet studied in formal trials. Tirzepatide is being evaluated in similar cardiovascular and inflammatory contexts; our Ozempic vs Mounjaro guide covers how the two drugs compare on cardiovascular outcomes and anti-inflammatory markers.
Non-alcoholic fatty liver disease (NAFLD/NASH). Semaglutide has shown significant reductions in liver inflammation (steatohepatitis) and fibrosis in phase 2 trials. The mechanism is well-characterized and includes both direct hepatic GLP-1 receptor activation and indirect reduction of visceral adipose-driven inflammation.
Chronic kidney disease. Semaglutide received FDA approval in 2024 for reducing kidney disease progression in patients with type 2 diabetes and CKD. Reduction of renal inflammation is part of the proposed mechanism, alongside hemodynamic effects on intraglomerular pressure.
Neuroinflammation and neurodegenerative disease. GLP-1 receptors are present in the brain, and neuroinflammation is implicated in Alzheimer’s disease, Parkinson’s disease, and depression. The EVOKE and EVOKE Plus trials are examining semaglutide specifically for Alzheimer’s disease prevention and treatment, with results expected around 2027.
What Ozempic Is Not
It is important to be precise about what the evidence shows and what it does not.
Ozempic is not an anti-inflammatory drug in the traditional classification. It is not approved for treating any inflammatory condition except as part of its cardiovascular indication. It does not work through the same pathways as NSAIDs, corticosteroids, or biologic immunosuppressants.
The anti-inflammatory effects documented in clinical trials are likely part of a broader metabolic reprogramming, rather than targeted suppression of specific inflammatory pathways. This metabolic reprogramming also affects body composition, including lean mass and bone density, particularly during rapid weight loss. The effects are generally beneficial but are not a substitute for specific anti-inflammatory therapy in conditions like autoimmune disease.
Patients with inflammatory conditions who are also candidates for GLP-1 therapy for metabolic reasons may receive dual benefits. But the anti-inflammatory signal should not be the primary or sole justification for starting Ozempic in the absence of a metabolic or cardiovascular indication.
The Bottom Line on Ozempic and Inflammation
The evidence is clear that semaglutide reduces systemic inflammation markers substantially and that some of this effect is weight-independent. The SELECT trial’s cardiovascular benefit is likely partly mediated through this anti-inflammatory mechanism. The extension of this effect into neurological, hepatic, and renal contexts is an active and promising area of research.
For patients who have both a metabolic indication for GLP-1 therapy and an inflammatory condition, the overlap is worth discussing with their physician. Dietary choices during GLP-1 therapy also influence inflammatory markers; our Ozempic nutrition guide covers anti-inflammatory food strategies and how to structure eating during therapy. For patients seeking to use Ozempic primarily as an anti-inflammatory agent without a metabolic or cardiovascular basis, the evidence does not currently support that use.